Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 88

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 88
---
 development$1,541 $3,563 $(2,022)$3,730 $6,378 $(2,648)General and administrative1,164 1,506 (342)2,369 3,434 (1,065)Total operating expenses2,705 5,069 (2,364)6,099 9,812 (3,713)Loss from operations(2,705)(5,069)2,364 (6,099)(9,812)3,713 Interest income17 98 (81)33 238 (205)Other income, net151 - 151 182 - 182 Net loss$(2,537)$(4,971)$2,434 $(5,884)$(9,574)$3,690 

Three Months Ended June 30,Six Months Ended June 30,20252024Change20252024ChangeResearch and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$— $7 $(7)$— $61 $(61)INVINCIBLE-2 Study (Phase 2 Breast)— 117 (117)— 221 (221)INVINCIBLE-3 Study (Phase 3 Sarcoma)788 1,970 (1,182)2,383 3,388 (1,005)INVINCIBLE-4 Study (Phase 2 Breast)134 315 (181)197 315 (118)Other14 58 (44)14 58 (44)Clinical trial expenses936 2,467 (1,531)2,594 4,043 (1,449)Contract manufacturing6 417 (411)29 631 (602)Salaries and benefits related costs292 448 (156)622 842 (220)Consulting & Other44 14 30 62 79 (17)Stock-based compensation263 217 46 423 783 (360)Total research and development expenses$1,541 $3,563 $(2,022)$3,730 $6,378 $(2,648)

Three Months Ended June 30,Six Months Ended June 30,20252024Change20252024ChangeGeneral and administrative expenses:Salaries and benefits related costs$234 $300